DTLL's tailored internalization into tumor parenchyma cells after specifically binding to EGFR/HER2 might contribute to blockage of their targeting pathways—the PI3K/AKT/mTOR signaling and PD‐L1‐medicated tumor escape from immunosurveillance. Here, EGFR is linked to neoplasm.